News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Targacept, Inc. (TRGT) Reports Fourth Quarter And 2013 Financial Results



2/13/2014 8:04:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the fourth quarter and year ended December 31, 2013. Targacept reported a net loss of $13.4 million for the fourth quarter of 2013, compared to a net loss of $15.9 million for the fourth quarter of 2012. For the year ended December 31, 2013, Targacept reported a net loss of $46.7 million, compared to a net loss of $7.0 million for 2012. As of December 31, 2013, cash and investments in marketable securities totaled $143.8 million.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES